A fillip for the pharmaceutical sector
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

A fillip for the pharmaceutical sector

Case of the Year: Neurim v UK government

circadin.jpg

The result

SPCs can be obtained for second medical use patents

The impact

A bonus for pharma companies investing in the development of products for different uses

The Court of Justice of the EU has little to do with patents (at least for now). So when it does rule in one of the limited patent-related areas over which it has jurisdiction, IP attorneys await its rulings with perhaps greater trepidation than normal. It was only last year, after all, that the Court curbed the patentability of human embryonic stem cells in Brüstle, a ruling that clarified the directive on the legal protection of biotechnological inventions.

But this year the Court gave pharmaceutical companies something of a fillip in a dispute related to supplementary protection certificates (SPCs). This is a sui generis right that effectively extends the life of a patent on a specific pharmaceutical-type product by compensating the owner for the time spent obtaining regulatory approval to put it on the market.

At the end of 2009, a hearing officer at the UK Intellectual Property Office IPO refused to grant Neurim an SPC for its product Ciracadin (melatonin). Circadin is used to treat insomnia and the basic patent concerns the use of melatonin to correct a distortion or deficiency in the plasma melatonin profile of humans.

The Office said that because melatonin had already been marketed since 2001 (by CEVA Animal Health under the name Regulin), Neurim's product was not eligible for an SPC. In particular, the hearing officer said that the intended use of the medicinal product could not be taken into account when considering the relevance of an earlier marketing authorisation.

The patent owner took the case to the High Court. At first instance, Mr Justice Arnold upheld the IPO's decision but the Court of Appeal later referred five questions to Europe's highest court. Writing for the Court of Appeal, Lord Justice Jacob (as he was then), made it clear that he thought the lower court had got it wrong. If its finding was right, he said, then "the Regulation will not have achieved its key objects for large areas of pharmaceutical research: it will not be fit for purpose. Whether that is so or not is clearly a matter for the EU's highest court".

Now the Court of Justice of the EU has offered its support to Jacob's interpretation of the rules on SPCs.

"The mere existence of an earlier marketing authorisation obtained for a veterinary medicinal product does not preclude the grant of a supplementary protection certificate for a different application of the same product for which a marketing authorisation has been granted," said the Court, "provided that the application is within the limits of the protection conferred by the basic patent relied upon for the purposes of the application for the supplementary protection certificate."

The ruling was good news for Neurim and other pharmaceutical companies investing in the development of products for different uses. But like a number of Court of Justice rulings, it leaves questions unanswered. Is there, for example, a distinction between obtaining earlier marketing authorisation for veterinary use of a product and human use? While IP owners welcomed Neurim, it was far from being the last word on SPCs.

Case details

Neurim v UK government

Patent number: EP (UK) 0 518 468

Invention: Melatonin to treat insomnia (branded as Circadin)

Technology: Pharmaceuticals

Patent owner: Neurim Pharmaceuticals

Other party involved: UK IPO

Courts: Court of Justice of the EU following a referral by the Court of Appeal in London

For Neurim: Carpmaels & Ransford

For the UK government: S Ossowski and A Robinson as agents and Charlotte May

This case was selected as one of Managing IP’s Cases of the Year for 2012.

To see the rest, click on one of the cases below.

The 10 cases of the year

A fillip for the EU pharmaceutical sector

Relief for trade mark owners in red sole saga

Australian TV streaming service held to be illegal

Smartphone war hits front page in the US

Liberalising the EU’s software market

India allows parallel imports

Victory for fair dealing in Canada

Lacoste loses its trade mark in China

Google prevails in Android attack

EU test case clarifies class headings

Ten you might have missed

Canada: Ambiguous claims can invalidate patents

Russia: Certainty on parallel imports

Italy: TV formats win copyright for the first time

First FRAND cases litigated worldwide

Monsanto loses in Brazil

Data exclusivity backed by Mexican courts

China: A shift over OEM manufacturing

Authors in the US able to reclaim joint copyrights

Germany: Knitted trainers a sign of the future

India: Financial Times loses trade mark

more from across site and ros bottom lb

More from across our site

A 36-member team from Zhong Lun Law Firm, including six partners, will join the newly formed East IP Group
The Delhi High Court sided with Ericsson against Indian smartphone maker Lava, bringing the companies' nine-year dispute to a close
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Tennessee has passed the ELVIS Act, a law that fights against AI models that mimic the voice and likeness of music artists
Rob Stien, chief communications and public policy officer at InterDigital, says the EU has forgotten innovators while trying to solve an issue that doesn’t exist
As Australia’s Qantm IP leans towards being acquired by a private equity company, sources discuss what it could mean for IP firms
Law firms that are conscious of their role in society are more likely to win work, according to a survey of over 23,000 in-house professionals
Nghiem Xuan Bac Pham, managing partner of Vision & Associates, discusses opportunities created by the US-China rift as well as profitability issues facing IP practices
Douglas Leite and two of his colleagues were intrigued by Bhering Advogados’s mission to grow its patent litigation practice
Each week Managing IP speaks to a different IP practitioner about their life and career
Gift this article